Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWLolamicin is a Gram-negative-selective antibiotic.1 It is selective for Gram-negative pathogenic bacteria, such as E. coli, S. typhimurium, and E. cloacae (MICs = 0.008-8 µg/ml), over Gram-negative commensal bacteria and Gram-positive pathogenic and commensal bacteria (MICs = >128 µg/ml). Lolamicin is also active against multidrug-resistant clinical isolates of E. coli, K. pneumoniae, and E. cloacae. Lolamicin-resistant bacteria contain mutations in LolC and LolE, which encode subunits of the LolCDE lipoprotein transport system. In vivo, lolamicin (100 mg/kg) increases survival and decreases lung colony-forming units (CFUs) in multiple mouse models of septicemia and pneumonia, respectively. It also does not affect fecal bacterial taxonomic composition in healthy mice nor allow C. difficile colonization in C. difficile-challenged mice when administered at a dose of 200 mg/kg.
WARNING This product is not for human or veterinary use.
1. A Gram-